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To compare frequency and functional activity of peripheral blood (PB) Th(c)17, Th(c)1 and Treg cells and
the amount of type 2 cytokines mRNA we recruited SLE patients in active (n = 15) and inactive disease
(n = 19) and healthy age- and gender-matched controls (n = 15). The study of Th(c)17, Th(c)1 and Treg
cells was done by ﬂow cytometry and cytokine mRNA by real-time PCR. Compared to NC, SLE patients
present an increased proportion of Th(c)17 cells, but with lower amounts of IL-17 per cell and also a
decreased frequency of Treg, but with increased production of TGF-b and FoxP3 mRNA. In active com-
pared to inactive SLE, there is a marked decreased in frequency of Th(c)1 cells, an increased production
of type 2 cytokines mRNA and a distinct functional proﬁle of Th(c)17 cells. Our ﬁndings suggest a func-
tional disequilibrium of T-cell subsets in SLE which may contribute to the inﬂammatory process and dis-
ease pathogenesis.
 2010 Elsevier Inc. All rights reserved.1. Introduction
Until very recently, the dominant paradigm for understanding
the pathogenesis of autoimmune diseases, including Systemic Lu-
pus Erythematosus (SLE) stated that Th1 and Th2 cells orchestrate
autoimmune responses [1]. Some studies suggested that Th2 cells
(producers of IL-4 and IL-10) were the key mediators [2–4] while
others emphasized the role of Th1 cells (producers of IFN-c, IL-2,
TNF-a) in SLE [5]. The discovery of a new subset of CD4+ T cells,
named Th17 after their signature cytokine, IL-17 is originating a
major revision in this paradigm. Many recent studies suggest that
Th17 cells are the primary drivers of inﬂammatory responses in a
variety of autoimmune diseases, including Crohn’s disease, rheu-
matoid arthritis and multiple sclerosis [6,7]. The role of IL-17 pro-
ducing cells in SLE pathogenesis is far less clear [8]. Some studies in
mouse models and in human lupus provide evidence for a role of
IL-17 [9–11], while others argue against this [12,13]. Studies onll rights reserved.
ocompatibilidade do Centro,
1-301 Coimbra, Portugal. Fax:
(A. Paiva).the inﬂuence of IL-17 in SLE disease activity are scarce and results
are contradictory [8]. In the CD8+ T cell compartment, Tc1 and Tc2
subsets exist, characterized by the same hallmark cytokines as Th1
and Th2, respectively. Recently, a subpopulation of CD8+ T cells
producing IL-17 (Tc17) was also discovered [14–16], but its role
in SLE has not been examined. It has been suggested that regula-
tory T (Treg) cells (TGF-b producers another T-cell subset with an
important role in suppressing autoimmunity may be defective in
SLE [17,18]. A reciprocal relationship exists between these differ-
ent T-cell subsets. Development of Th1 and Th2 subsets is mutually
antagonistic and both cell types suppress Th17 [19,20]. Treg cells
suppress other effector T cells but, surprisingly, Treg-derived
TGF-b enhances Th17 differentiation [21,22].
Because SLE immune response is highly heterogeneous and in
view of the reciprocal interrelationships of the T cell subpopula-
tions, the role of Th(c)17 cells in SLE might be better elucidated
with integrated evaluation of their cytokine production.
The aim of this study was to evaluate and compare the fre-
quency and functional activity of Th17 cells and other peripheral
blood T-cell subsets, namely Th(c)1, Tc17 and Treg cells, and the
production of type 2 cytokines mRNA in active and inactive SLE
and in healthy control subjects.
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2.1. Patients
We recruited patients with SLE fulﬁlling the 1997 ACR classiﬁ-
cation criteria for the disease [23,24]. Disease activity at the time
of evaluation was scored according to the Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI, 2000) [25,26]. Patients
were divided into two groups, according to their SLEDAI score (ac-
tive disease = SLEDAIP 5) [27]. Medication at time of evaluation
was recorded.
2.2. Controls
As controls, we recruited healthy age- and gender-matched
bone marrow donors at the Histocompatibility Center of Coimbra.
Pregnancy and age under 18 were exclusion criteria for participa-
tion. The study protocol was approved by the local ethics commit-
tee. All participants gave and signed informed consent.
2.3. Blood samples
One 20 mL PB sample was collected from each participant on
the day of inclusion and clinical evaluation. Samples were sent to
the laboratory identiﬁed with a code number and analysis was per-
formed without knowledge of the participant disease status.
2.4. Immunoﬂuorescence staining of peripheral Th(c)1 and Th(c)17
subsets after in vitro stimulation with PMA/ionomycin, in the presence
of Brefeldin A
500 microliters of each PB sample were diluted L/L (vol/vol), in
RPMI-1640medium (Gibco; Painactive SLEy, Scotland, UK), supple-
mented with 2 mM L-glutamine. About 50 ng/mL of phorbol
12-myristate 13-acetate (PMA; Sigma, Saint Louis, MO, USA),
1 lg/mL of ionomycin (Boehringer Mannheim, Germany) and
10 lg/mL of Brefeldin A (Golgi plug-Sigma, Saint Louis, MO, USA)
were added and the sample was incubated for 4 h at 37 C in a
humidiﬁed incubator with 5% CO2 concentration.
Each cultured PB sample was aliquoted and stained in three dif-
ferent tubes (200 mL/tube) following an intracytoplasmatic per-
meabilization and staining protocol in order to analyse
separately the intracellular expression of IL-2, TNF-a and IFN-c
in IL-17-positive and IL-17-negative T cell subpopulations, within
CD4 T cell and CD8 T-cell subsets. All cell aliquots were stained
with IL-17 PE (clone 41802; R&D Systems, Europe) and separately
with IL-2 (clone MQ1-17H12; BD Pharmingen, San Diego, CA, USA),
TNF-a (clone MAb11; BD Pharmingen, San Diego, CA, USA) and
IFN-c (clone 4S.B3; BD Pharmingen, San Diego, CA, USA) according
to the manufacturer’s instructions for ﬁxation and permeabiliza-
tion. These mAb were added to each tube after staining cells for
surface expression of mAb directed against T lymphocytes subsets
– anti-CD3-PerCP (clone SK7; BD, San Jose, CA, USA) and anti-CD8
APC (clone SK1; BD, San Jose, CA, USA). Among positive CD3 cells,
CD4 positive T cells were identiﬁed after exclusion of cd-T-cell sub-
set according to their higher reactivity with anti-CD3 monoclonal
antibody and typical light scatter.
2.5. Immunoﬂuorescent staining of peripheral regulatory T cells (Treg)
In aliquots corresponding to Treg evaluation, anti-CD25-FITC
(clone M-A251; Pharmingen BD, San Diego, CA, USA), anti-CD127
PE (clone hIL-7R-M21; BD, San Jose, CA, USA), and anti-CD4
PerCP-cy5.5 (clone SK3; BD, San Jose, CA, USA), were added and
the samples were incubated for 15 min at room temperature indarkness. After this incubation period, 2 mL of FACS Lysing Solu-
tion (BDB, San Jose, CA) diluted 1:10 (vol/vol) in distilled water
was added and after 10 min of incubation the cells were washed
with 2 mL of PBS and resuspended in 0.5 mL of PBS before analysis
in ﬂow cytometry.
2.6. Flow cytometric analysis
Single-cell suspensions were prepared and stained for 15 min at
room temperature in darkness with optimal dilutions of each mAb.
Results illustrate the percentage of positive cells within each cell
subset or/and their mean ﬂuorescence intensity (MFI). T lympho-
cytes were identiﬁed according to their positivity for CD3 and typ-
ical light scatter. The cytokine production was evaluated within the
different T-cell subsets on an electronic CD3+ gating, after a ﬁrst
acquisition of 20,000 of total events. The identiﬁcation and quanti-
ﬁcation of Treg were done based on the following phenotype:
CD4+, CD25bright and CD127/low expression. Finally, expression of
cell surface markers and production of cytokines were assessed
using the ﬂow cytometer (FACSCalibur; BD, San Jose, CA, USA),
and data were analysed using Inﬁnicyt software (Cytognos, Spain).
2.7. Treg cell sorting
As other researchers, we used the expression of CD127 as a via-
ble surface biomarker to differentiate effector (CD127+) cells from
Treg (CD127/low) cells in humans [12]. Thus, CD25bright/CD127low
CD4 T cells, deﬁned as Treg cells in our experiments, were puriﬁed
using a FACSAria cell sorter (BD, San Jose, CA, USA). The purity of
the isolated cell populations was evaluated and it was consistently
greater than 90%.
2.8. Gene expression analysis
Study of mRNA expression of IL-4 and IL-10 from whole blood
was performed in blood collected collection in PAXgene Blood
RNA Tube (PreAnalytiX GmbH, Switzerland) with automated RNA
puriﬁcation in QIAcube (Qiagen, Hilden, Germany). Total RNA iso-
lation from sorted Treg cells was performed using RNeasy Micro
Kit (Qiagen, Hilden, Germany).
RNA integrity and quantiﬁcation were analyzed using 6000
Nano Chip Kit, in Agilent 2100 bioanalyzer (Agilent, Walbronn,
Germany). One microgram of RNA was reverse transcribed with
SuperScript™ III First-Strand Synthesis System for RT-PCR (Invitro-
gen, CA, USA) using oligo(dT) plus random hexamers according to
manufacturer’s instructions.
Relative quantiﬁcation of gene expression by real-time PCR was
performed using thermocycler LightCycler 480 II (Roche, Basel,
Switzerland). Normalization for gene expression quantiﬁcation
was performed with geNorm Housekeeping Gene Selection Human
Kit (Primer Design, Southampton, UK) and geNorm software
(Ghent University Hospital, Center for Medical Genetics, Ghent,
Belgium) to select optimal housekeeping genes to this study [28].
Real-time PCR reactions used speciﬁc QuantiTect Primer Assays
(Qiagen, Hilden, Germany) with optimized primers for IL-4
(QT00012565), IL-10 (QT00041685), FOXP3 (QT00048286), TGFB1
(QT00000728) and endogenous controls ATP5B (QT00055622), B2M
(QT00088935), RRN18S (QT00199367) and SDHA (QT01668919) to-
getherwith QuantiTect SYBRGreen PCRKit Gene expression (Qiagen,
Hilden, Germany) according to manufacturer’s instructions. Reac-
tions were performed with the following thermal proﬁle: 10 min at
95 C plus 40 cycles of 15 s at 95 C, 30 s at 60 C and 30 s at 72 C.
Quantitative real-time PCR results were analyzed with Lightcycler
480 software (Roche, Basel, Germany) and quantiﬁcation was per-
formed in qBasePlus software package (Biogazelle, Zulte, Belgium).
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Statistical evaluation of data were analysed using the non-para-
metric Mann–Whitney U test and correlations between the groups
were assessed by non-parametric Spearman correlation. Results
were expressed as the mean ± SD (median). All statistical analyses
were performed using SPSS Inc., Chicago, USA and differences were
considered as statistically signiﬁcant when the p value was less
than 0.05.3. Results
3.1. Study population: SLE patients with active and inactive disease
and healthy controls
Forty-seven subjects were enrolled in the study, comprising
thirty-four SLE patients, 15 with active disease (86.7% female,
mean age 32 ± 11 years) and nineteen with inactive disease
(89.5% female, mean age 34 ± 9 years). Thirteen sex-and age-
matched healthy control subjects (NC group) (76.9% female,
mean age 34 ± 10 years) were also included. Mean SLEDAI scores
in the active SLE and inactive SLE group, was 10.3 ± 3.53 and
2.7 ± 1.52, respectively. The time since diagnosis was 9 ± 5 years
in both groups. Lupus nephritis was the most prevalent major or-
gan involvement, diagnosed in 66.7% of active SLE and 52.6% of
inactive SLE cases. Three patients had neurolupus, all from the
inactive SLE group. Prevalence of lupus arthritis was 93.3% in
the active SLE group and 68.4% in the inactive SLE group. Haema-
tological involvement was present in 93.3% of active SLE and in
84.2% of inactive SLE group patients. Lupus skin disease was
found in 80% of active SLE and 52.6% of inactive SLE patients.
At time of evaluation, patients with active SLE and inactive SLE,
respectively, were receiving treatment with hydroxychloroquine
in 80% and 94.7% of cases, prednisone 93.3% and 42.1% (mean
daily dose 18.2 mg and 5.3 mg) and immunosuppressants
(micofenolate mofetil, azatioprine or cyclosporine) in 53.3% and
31.6%, respectively.3.2. Frequency of major peripheral T cell subpopulations
The patients with active SLE presented a lower percentage of
CD4 PB T cells as compared to NC [active SLE: mean CD4 T cells =
61.1 ± 10.5%; NC: mean CD4 T cells = 72.3 ± 6.0% (p < 0.05)]. There
was no statistically signiﬁcant difference between NC and inactive
SLE.3.3. Functional characterization of peripheral Th1 and Tc1 cells
Compared to inactive SLE and NC subjects, active SLE patients
presented a signiﬁcantly lower proportion of CD4 and CD8 T cells
producing IL-2, TNF-a and IFN-c (Table 1). However, when we ana-
lysed the amount of each studied cytokine at single cell level (i.e.,
mean ﬂuorescence intensity, MFI), there was an increased expres-
sion of IL-2 in Th1 cells of active SLE patients compared to inactive
SLE and NC (p < 0.05). No other signiﬁcant functional differences
were found between the 3 groups, in both Th1 and Tc1 cell subsets
(Table 1).3.4. Expression of IL-4 and IL-10 mRNA in whole blood collection
The IL-10 and IL-4 mRNA expression was signiﬁcantly higher in
active SLE patients when compared to NC and inactive SLE patients
(p < 0.05), without differences between inactive SLE and NC
(Fig. 1).3.5. Frequency and functional characterization of peripheral Th17 and
Tc17 cells
The proportion of IL-17-producers among CD8+ cells (Tc17)
was signiﬁcantly higher in active SLE compared to NC
(p < 0.05). A similar trend was observed for Th17 in both ac-
tive and inactive SLE, but did not reach statistical signiﬁcance
(Table 2). No differences were observed in the frequency of
Th17 and Tc17 cells between active SLE and inactive SLE
groups.
In contrast, analysis of the amount of IL-17 produced at single
cell level (MFI) suggested a decreased expression of IL-17 in
Th17 and Tc17 subpopulations of SLE subjects compared to NC
subjects. This reached a statistical signiﬁcance for both Th17 and
Tc17 cells in active SLE and Th17 in inactive SLE compared to NC
(p < 0.05) (Table 2).
In an attempt to more thoroughly understand the functional
activity of Th17 and Tc17 populations in SLE patients, we studied
the frequency of those cells producing the pro-inﬂammatory cyto-
kines IL-2, TNF-a and IFN-c and the amount of each studied cyto-
kine at single cell level. In NC and in both SLE groups, around 60%
of Th17 cells simultaneously secreted IL-2 and 78–90% secreted
TNF-a. In contrast, less than 20% of those cells were producing
IFN-c. Likewise, 40–60% of NC and SLE Tc17 cells produce IL-2
and 60–80% secrete TNF-a, while less than 40% were secreting
IFN-c Table 3. As shown in Table 3, there was a marked heteroge-
neity in the proportion of Th17 and Tc17 cells producing pro-
inﬂammatory cytokines, particularly for Tc17 from all groups. Both
IL-17+ T-cell subsets producing TNF-a and the Tc17 producing IFN-
c showed lower frequency in active SLE compared to NC (p < 0.05).
In addition, regarding pro-inﬂammatory cytokine levels in Th17
and Tc17 cells, we observed higher levels of IL-2 in Th17 cells from
the active SLE group compared to inactive SLE and NC (p < 0.05),
without other signiﬁcant differences between groups. Cytokine
production evaluated through MFI was much higher for TNF-a
than the other studied cytokines in Th(c)17 cells from NC and
SLE subjects (Table 3).3.6. Frequency of peripheral regulatory CD25bright/CD127low CD4+ T
cells
Considering the possible lymphopenia that may occur in pa-
tients with SLE, we measured the absolute number of peripheral
CD25+/CD127low CD4+ T cells, which were deﬁned as T regula-
tory cells (Treg) in our experiments. We found a signiﬁcantly low-
er absolute number (cells/ll of PB) and relative frequencies of
Treg in active SLE and inactive SLE compared to NC (p < 0.05),
particularly in the active SLE group (Table 2). On the other hand,
the percentage of Treg cells in the CD4 T-cell subset was similar
in the three studied groups (Table 2). The Treg frequency among
CD4 T cells in the NC group was inversely correlated with the
proportion of TNF-a producing Th1 cells (p = 0.02; r2 = 0.35), but
no signiﬁcant correlation was observed in the SLE group. No cor-
relation was found between frequency of Treg and Th17 or Tc17
cells.3.7. Functional characterization of peripheral regulatory CD25bright/
CD127low CD4+ T cells by gene expression of FoxP3 and TGF-b1
After cell sorting of CD4+CD25brightCD127low Treg, we observed
in these cells a signiﬁcant increase of FoxP3 and TGF-b1 mRNA in
SLE patients comparatively to NC subjects (p < 0.05). Also, there
was a trend for an increase in FoxP3 and TGF-b1 gene expression
in the active SLE group compared to NC and inactive SLE groups
(Fig. 2).
Table 1
Frequency of cytokines producing T cells (Th1 and Tc1) and amount of each cytokine per cell (MIF), following PMA/ionomycin activation.
NC ASLE ISLE
Th1
IL-2 % 39.2 ± 13.9 (40.4) 25.9 ± 11.3 (24.5)a,b 38.5 ± 10.6 (40.5)
MFI 107.4 ± 43.9 (106.1) 172.8 ± 40.2 (177.0)a,c 131.6 ± 46.9 (119.1)
TNF-a % 57.9 ± 15.7 43.2 ± 16.7 (43.6)c 55.9 ± 14.7 (60.7)
MFI 327.9 ± 160.5 (265.4) 307.2 ± 157.7 (290.2) 336.4 ± 92.4 (324.3)
IFN-c % 25.6 ± 6.4 (26.2) 13.1 ± 6.4 (15.3) 24.6 ± 12.1 (22.7)
MIF 294.1 ± 89.0 (327.3) 309.0 ± 78.8 (321.1) 320.3 ± 75.0 (298.4)
Tc1
IL-2 % 12.5 ± 6.9 (11) 8.1 ± 3.7 (7.5) a,c 16.9 ± 7.8 (16.8)
MFI 60.9 ± 13.0 (64.0) 73.6 ± 18.7 (68.5) 69.9 ± 36.6 (59.5)
TNF-a % 49.1 ± 14.2% (45.0) 25.2 ± 11.5 (23.4)a,c 46.8 ± 14.1 (45.8)
MFI 313.1 ± 119.1 (348.6) 263.5 ± 100.2 (231.5) 334.6 ± 121.8 (297.0)
IFN-c % 46.8 ± 12.6 (50.0) 29.0 ± 15.5 (25.8) 43.8 ± 15.0 (43.3)
MFI 248.9 ± 79.0 (268.3) 270.9 ± 85.2 (294.3) 269.9 ± 72.9 (264.3)
Results are expressed as mean ± standard deviation (median). %, percentage of positive cells; MFI, mean ﬂuorescence intensity of positive cells. NC, healthy individuals, ASLE,
active disease, ISLE, inactive disease. Statistically signiﬁcant differences were considered when p < 0.05 (Mann–Whitney U test).
a ASLE versus NC.
b ISLE versus NC.
c ASLE versus ISLE.
Table 2
Comparative analysis of the overall proportion of Th17, Tc17 and Treg in healthy and
patient groups.
NC ASLE ISLE
Th17
%CD4+ 1.6 ± 0.7 1.9 ± 1.5 2.0 ± 1.2
MFI 90 ± 20 66 ± 17a 63 ± 21b
Tc17
%CD8+ 0.3 ± 0.1 0.6 ± 0.4a 0.7 ± 0.8
MFI 87 ± 40 67 ± 33a 68 ± 27
Treg
% 0.9 ± 0.3 0.4 ± 0.4a 0.7 ± 0.4b
%CD4+ 7.1 ± 2.7 8.1 ± 3.7 8.2 ± 3.5
Cells/ll 0.07 ± 0.02 0.03 ± 0.03a 0.06 ± 0.06b
Results are expressed as mean ± standard deviation. MFI, mean ﬂuorescence
intensity of positive cells; %, percent of cells from total PB; %CD4+, percent of cells
from total peripheral CD4+ T cells; %CD8+, percent of cells from total peripheral
CD8+ T cells; NC, healthy individuals, ASLE, active disease, ISLE, inactive disease.
Statistically signiﬁcant differences were considered when p < 0.05 (Mann–Whitney
U test).
a ASLE versus NC.
b ISLE versus NC.
Fig. 1. Graphic of IL-4 and IL-10 relative gene expression in whole blood cells for
SLE patients group and the NC. *Statistically signiﬁcant differences (p < 0.05) when
compared ASLE patients with control group.
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A central role for the recently discovered Th17 cells as the pri-
mary drivers of autoimmune diseases, including SLE, has been pro-
posed [8], but the potential role of Th17 cells in SLE is far from
clear. The Th17 have functional reciprocal interrelationships withthe classic Th1, Th2 and Treg cells, which are important players
in regulating immune responses and in SLE pathogenesis
[19,21,22]. In the CD8+ T cell compartment, a Tc17 subset was
newly discovered [14] that might also play a role in autoimmune
diseases [16].
This is the ﬁrst study that evaluates the relative abundance and
functional activity of Th17 and Tc17 cells in parallel with Th(c)1,
Treg and amount of mRNA type 2 cytokines in SLE. We showed that
an increased proportion of Th17 and Tc17 are present in the PB of
SLE patients. We also demonstrated that these cells produce not
only IL-17 but also that a considerable proportion produce TNF-a
and IL-2 with a minor proportion secreting IFN-c. We found a low-
er frequency of the peripheral blood CD4 T-cell subset in SLE pa-
tients and a signiﬁcant decrease in the frequency of Th1 and Tc1
cells producing Th1-type cytokines (IL-2, TNF-a and IFN-c) in pa-
tients with active disease, when compared with those with inac-
tive SLE and controls (Table 1). Interestingly, no differences were
observed between inactive disease state and NC group. In addition,
when we analysed the amount of each studied cytokine at single
cell level (MFI), we observed an increase only in the IL-2 content
on CD4 T-cell subsets, particularly in active SLE (Table 1).
Regarding the lower numbers of Th(c)1 cells observed in active
SLE in our study and considering the important concept that Th1 or
Th2 cells inﬂuence the homeostasis of each other [29,30], this de-
crease could be due to an enhancement of Th2 cell function. In this
sense, we analysed classical Th2-cytokines mRNA expression from
whole blood cells and demonstrated that T cells from SLE patients
could be preferentially polarized to a Th2 proﬁle since we observed
a higher amount of IL-10 and less markedly IL-4 mRNA. This may
result from a strong downregulation of Th1-secreting T cell popu-
lation size observed following PMA/I stimulation. It is unclear
whether only a small number of T cells or other cell types are in-
volved in the production of Th2 cytokines at a very high level or
whether many cells express small amounts of the respective
mRNA. Moreover, recent reports suggest that IL-10 might play a
potent inhibitory action on both Th1 and Th2 cell responses and
a major role in the development of Treg cells [31,32]. In our study,
we found a higher expression of IL-10 mRNA, and less clearly of IL-
4 in active SLE (Fig. 1), which could result in a reduction of Th(c)1
and Th(c)17 subpopulations. Indeed, a reduction in IFN-c-produc-
ing Th(c)1 cells, may contribute to the induction and maintenance
of autoimmunity in SLE by facilitating increased production of B
cell stimulatory cytokines by Th2 cells and enhancing the respon-
siveness of B cells to these cytokines [33]. The diverse immunosup-
pressive drugs received by SLE patients in our study, especially
Table 3
Frequency of cytokines producing T cells (Th17 and Tc17) and amount of each cytokine per cell (MIF), following PMA/ionomycin activation.
NC ASLE ISLE
Th17
IL-2 % 58.1 ± 17.8 (61.0) 61.6 ± 12.2 (64.1) 64.0 ± 18.3 (68.3)
MFI 120.5 ± 47.6 (114.1) 188.4 ± 51.8 (197.0)a,c 145.0 ± 47.3 (134.8)
TNF-a % 90.7 ± 4.1 (90.1) 85.5 ± 6.5 (85.7)a 78.4 ± 23.9 (90.0)
MFI 449.2 ± 225.7 (419.7) 464.5 ± 265.3 (383.1) 399.7 ± 171.6 (365.0)
IFN-c % 18.0 ± 5.3 (18.0) 13.2 ± 7.6 (11.6) 20.9 ± 19.7 (15.5)
MFI 154.6 ± 56.5 (142.0) 146.3 ± 55.6 (130.2) 182.9 ± 142.9 (136.3)
Tc17
IL-2 % 61.2 ± 13.7 (62.2) 48.7 ± 20.8 (54.6) 44.3 ± 20.5 (43.8)b
MFI 104.9 ± 54.8 (80.3) 113.9 ± 60.8 (98.9) 115.9 ± 46.9 (125.0)
TNF-a % 79.6 ± 16.1 (83.3) 59.4 ± 14.9 (66.7)a 65.4 ± 17.2 (70.3)
MFI 441.4 ± 244.4 (408.1) 339.5 ± 148.3 (316.0) 330.7 ± 228.4 (269.0)
IFN-c % 38.6 ± 14.0 (39.7) 20.3 ± 16.2 (13.1)a 42.6 ± 31.2 (38.8)
MFI 166.7 ± 56.8 (163.4) 169.0 ± 78.2 (177.3) 197.5 ± 103.3 (210.8)
Results are expressed as mean ± standard deviation (median). %, Percentage of positive cells; MFI, mean ﬂuorescence intensity of positive cells. NC, healthy individuals, ASLE,
active disease, ISLE, inactive disease. Statistically signiﬁcant differences were considered when p < 0.05 (Mann–Whitney U test):
a ASLE versus NC.
b ISLE versus NC.
c ASLE versus ISLE.
Fig. 2. Graphic of FoxP3 and TGF-b gene expression per cells (Treg) for SLE patients group and the NC (A and B, respectively). NC, healthy individuals; SLE, total SLE patients;
ASLE, active disease; ISLE, inactive disease. *Statistically signiﬁcant differences (p < 0.05) when compared total SLE patients with control group.
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[34,35] and contributed to the interindividual heterogeneity in fre-
quencies and functional activity.
Although Th1 subsets are thought to be crucial player for many
autoimmune diseases, like SLE, recent studies raise the possibility
of involvement of other Th subsets, different from Th1 cells in
the induction of autoimmunity.
IL-17 producing T cells are an effector T-cell subset involved in
inducing inﬂammation and autoimmune tissue injury [36]. In this
study, we found that the number of Th17 and Tc17 cells was ele-
vated in SLE patients compared to NC subjects (Table 2). This cor-
roborates the ﬁndings of the other available studies [10,11].
However, contrary to Yang et al., we did not ﬁnd differences in
Th17 frequencies between active and inactive SLE patients. The
Tc17 showed the same trend for higher frequency in SLE compared
to NC, again without differences related to SLE disease activity. To
our knowledge, this is the ﬁrst study to demonstrate the presence
and evaluate function of Tc17 cells in SLE. The role of these cells re-
mains unclear, however, their presence was demonstrated in a
mouse model of multiple sclerosis [16] and in psoriasis skin pla-
ques in humans [37]. Tc17 cells display a greatly suppressed cyto-
toxic function and share some key features with the Th17 subset[14,16,37]. We may speculate that Tc17 cooperate with Th17 in
similar functions in inﬂammatory conditions, including SLE and
other autoimmune diseases [16,37], infection [16,38] and antitu-
mor immunity [39].
When we studied the functional activity of IL-17 producing T
cells, we observed a decrease in the frequency of these cells pro-
ducing Th1-type cytokines (IL-2, IFN-c and TNF-a) in active SLE
(Table 3). Decreased production of TNF-a by Th(c)17 might have
important functional implications, as this cytokine exhibits potent
synergy with IL-17 for pro-inﬂammatory effects [40]. In addition,
and in contrast with the ﬁndings of Yang et al. [11] we observed
a functional abnormality of Th(c)17 cells, demonstrated by the
lower amounts of IL-17 per cell found in both groups of SLE pa-
tients (Table 2), which were not shown for type 1 cytokines. This
results observed in Th(c)17 cells could be explained, at least in a
certain extent, by the same reasons described for Th(c)1 cells, with
the exception that the number of Th(c)17 cells seem not to be af-
fected by therapy or by an increase of Th2 cytokines. We found a
great functional heterogeneity of Tc17 cells in SLE patients and
their sharing features with both Th1 and Th17. Production of
IFN-c and TNF-a by Tc17 cells was previously described [16], but
to our knowledge, our data are the ﬁrst in SLE. Despite the appar-
102 A. Henriques et al. / Cellular Immunology 264 (2010) 97–103ent discrepancies between studies, presence of Th17 and Tc17 cells
suggests they might contribute to acute and chronic inﬂammation
in SLE [19,41,42].
The Treg plays a fundamental role in suppression of autoimmu-
nity [43] and at the same time have a reciprocal relationship with
the Th17 that drives it, as Treg-derived TGF-b is an important
inductive cytokine for Th17 development in humans [44]. The
Tc17 follow a similar developmental process induced by TGF-b
[16]. We investigated the interrelationships of these subsets in
SLE in our study. We found a signiﬁcantly lower absolute number
and relative frequencies of Treg (Table 2), but with a signiﬁcant in-
creased FoxP3 and TGF-b1 mRNA in SLE patients compared to NC
(Fig. 2). However, there were no signiﬁcant differences related to
SLE activity (Fig. 2). Furthermore, no signiﬁcant correlations were
found between Treg and Th(c)17 or Th(c)1 subsets in these sub-
jects. The published studies on the phenotype and functional activ-
ity of Treg in SLE patients are contradictory. Some other studies,
but not all, also report that Treg are numerically decreased in SLE
[45]. Contrary to our results, several studies have suggested that
Treg are functionally defective during active SLE [46–48]. Miyara
et al. [17] suggested that an increased sensitivity of Treg cells in
SLE patients to Fas-mediated apoptosis might account for the re-
duced number of Treg cells observed, particularly in patients with
active disease. The immunosuppressive treatment may also have
an adverse impact on Treg cell frequency in our patients, particu-
larly in those with active disease. The decreased numbers of Treg
might contribute to the deregulation of T cell homeostasis via
IL-10 and TGF-b production [49,50] and consequently to the path-
ogenesis of SLE in humans.
In summary, we found in SLE patients compared to NC a trend
for increased proportion in Th(c)17 cells, but with lower IL-17 pro-
duction and also a decreased frequency of Treg, but with increased
production of TGF-b and FoxP3. In active compared to inactive SLE,
there is a decreased proportion of Th(c)1 cells, an increased pro-
duction of type 2 cytokines mRNA and a distinct functional proﬁle
of Th(c)17 cells. Taken together, our ﬁndings suggest a functional
disequilibrium of T-cell subsets in SLE that might contribute to
the inﬂammatory process and draw novel insights on a hypothet-
ical driving role of Th17 and Tc17 cells on disease pathogenesis.
SLE is a very heterogeneous disease in clinical grounds and we also
found high heterogeneity in T-cell subsets and respective func-
tional activity. For further understanding role of T-cell subset
dynamics in driving SLE disease activity, there will be needed lon-
gitudinal studies.References
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